Charlotte's Web (CWBHF) Q4 2025 earnings summary

Executive summary

• Announced a transformative transaction with BAT, converting $55M in debt plus $10M interest into equity and adding $10M in new capital, eliminating major liabilities and strengthening the balance sheet.

• Achieved first annual revenue growth since 2021, with 0.5% year-over-year increase to $49.9M in 2025, driven by new product launches and digital marketing improvements.

• Positioned as a leader in the CMMI Medicare pilot, enabling access to CBD products for seniors through federally authorized programs, with broader expansion expected in 2027.

• Advanced DeFloria, a joint venture, into FDA phase II clinical trials for autism-related irritability, leveraging proprietary CBD extracts and holding exclusive manufacturing rights.

• Achieved significant cost reductions and operational improvements, including a gold-standard manufacturing compliance audit.

Financial highlights

• Q4 2025 net revenue was $13.3M, up 15.8% sequentially and 4.7% year-over-year, driven by direct-to-consumer growth and product innovation.

• Q4 gross profit was $5M with a 37.5% margin, impacted by a $1.3M non-recurring inventory charge; underlying margin improved due to in-house manufacturing and channel mix.

• Full-year 2025 net revenue was $49.9M, up 0.5% year-over-year; SG&A expenses fell 21.2% to $42M.

• Full-year net loss was $29.7M ($0.19/share), flat year-over-year; operating loss improved 36.6% to $20.3M.

• Cash and equivalents at year-end were $8M, with working capital of $21.7M.

Outlook and guidance

• Gross margin expected to normalize toward 50% as transitional items are lapped and efficiencies scale.

• Quarterly SG&A for core business expected to remain at $10M-$11M, excluding Medicare program launch costs.

• Early days for CMMI pilot; gradual revenue build expected over 12-18 months, with significant long-term TAM as Medicare Advantage expands.

• In-house manufacturing and cost controls are projected to further enhance margins and cash flow.

• Confident in readiness for regulatory changes and scaling opportunities.